Parkinson’s Disease and OCD are Likely to Affect the Deep Brain Stimulation Model Market

Image of Blog

Deep brain stimulation (DBS) is an electrical device that is placed inside the human body through surgery. It is often described as the brain pacemaker. It is used to treat neurological afflictions like Parkinson’s disease, multiple sclerosis, dystonia, obsessive-compulsive disorder, epilepsy, essential tremor, etc. An increase in the number of any of these illnesses, along with the increase in the demand for minimally invasive procedures and investment in neurological research and development, can drive the market growth. Also rise in more technologically advanced products like Boston Scientific Corporation’s Vercise Deep Brain Stimulation (DBS) System with a rechargeable battery that can last for 25 years, the longest battery life offered by any DBS machine till now, and a surge in the aging population can also increase the market share significantly during the forecast period. With the unanticipated outbreak of coronavirus at the end of 2019, the market is facing a hard time since suppliers and consumers of the product are unable to meet at a common ground. 

Dual Channel and Single Channel Deep Brain Stimulation Devices 

The dual-channel DBS devices are amongst the safest and effective devices that are used in a surgical procedure. This segment has dominated the market since 2019. Attributed to an increasing number of hospitals, like MAX Saket, New Delhi, they are utilizing dual channel DBS device systems in the patients who have Parkinson’s disease. Dual DBS devices have been reported to provide more programming alternatives to the neurosurgeons, which led to an increase in its demand. 

Higher Number of Parkinson’s Disease and Obsessive-Compulsive Disorder (OCD) Can Affect the Market

An escalation in the number of Parkinson’s disease in people can boost the DBS market growth. A study conducted by Parkinson’s Foundation revealed that 60,000 people are affected by this disease every year in the U.S. The Vercise was invented in 2012, but it received FDA approval in 2017. Thus, if these U.S. FDA approvals and the number of Parkinson’s disease patients continue to increase globally, the market can face a boom. 

A surge in the obsessive-compulsive disorder cases facing failed therapies is expected to drive the market for DBS device systems as they provide long term treatment and improved effects. The European Union, Australia have already approved the use of DBS therapy for OCD over other therapies and the U.S. and hence provides a significant contribution to market growth.

Major Market Competitors

Some major companies in the market are Abbott Laboratories, Bionic Enterprises, Boston Scientific Corp., Aleva Neurotherapeutics SA, Medtronics, SceneRay, Enteromedics, Cyberonics inc., and Neuronitcs, and Deep Brain Innovations, among others.  In 2020, Medtronics launched a CE (Conformité Européenne) mark for its PC (Percept) neurostimulators. This is a DBS system with a BrainSense technology; it can sense and record the brain signals while it delivers therapy to the patient. 

Further, in 2019 Medtronics launched Activa neurostimulators in California which help in the treatment of patients suffering from essential tremors and the associated symptoms. In the same year Boston Scientific Corp. Launched two devices called Vercise primary cell and Vercise Gevia DBS system in America. Thus, these companies are investing a lot of their money on research and development for newer and better products along with building growth strategies to launch these devices into different countries across the globe.

 

Recent Posts
Validation error occured. Please enter the fields and submit it again.